Welcome to our dedicated page for Chemomab Therapeutics SEC filings (Ticker: CMMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Chemomab Therapeutics Ltd. (CMMB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Chemomab files annual reports on Form 20-F and current reports on Form 6-K, which together offer insight into its clinical-stage biotechnology business focused on nebokitug, a monoclonal antibody targeting CCL24 in fibro-inflammatory diseases such as primary sclerosing cholangitis (PSC).
Through its Form 6-K submissions, Chemomab furnishes press releases, unaudited condensed consolidated financial statements, and management’s discussion and analysis for interim periods. These filings detail research and development spending, general and administrative expenses, cash resources and liquidity outlook, as well as narrative updates on the nebokitug development program, including the Phase 2 SPRING trial in PSC and preparations for a planned Phase 3 registration study. Certain 6-Ks also incorporate by reference financial tables, interactive data files and other exhibits into the company’s shelf registration statements and equity compensation plans.
Investors can also review filings that describe capital markets activities, such as at-the-market (ATM) equity offering programs and changes to the ratio of American Depositary Shares (ADSs) to ordinary shares, which effectively function as reverse ADS splits. These documents outline the terms under which Chemomab may sell ADSs, the role of its sales agent, and related legal opinions. Additional 6-Ks report outcomes of shareholder meetings, including director elections, equity awards and auditor appointments.
For those analyzing Chemomab’s governance and regulatory status, the filings page is a central source for information on registration statements on Form F-3 and Form S-8, as well as references to risk factor discussions in the company’s Form 20-F. While detailed clinical protocols and scientific data are often summarized in attached press releases, the SEC filings frame how these developments fit into Chemomab’s overall business, financing strategy and regulatory obligations.
On Stock Titan, these documents are complemented by AI-powered tools that can summarize lengthy filings, highlight key sections related to nebokitug’s PSC program, and help users quickly locate information on topics such as liquidity, share structure changes, or the incorporation by reference of new disclosures into existing registration statements.
OrbiMed Israel and affiliated entities have filed Amendment No. 5 to Schedule 13D reporting their exit from a significant ownership position in Chemomab Therapeutics Ltd (NASDAQ: CMMB). The filing indicates that following a major transaction, the reporting persons have ceased to be beneficial owners of more than 5% of the company's shares.
Key details of the transaction and current holdings:
- On June 18, 2025, OrbiMed Israel Partners (OIP) sold 1,610,000 American Depositary Shares at $1.10 per ADS
- Current holdings include 131,273 ADSs, 28,817 Warrants, and 809,717 Pre-Funded Warrants
- Total beneficial ownership now represents approximately 4.8% of outstanding shares
The reporting group includes OrbiMed Israel GP Ltd, OrbiMed Israel BioFund GP Limited Partnership, Carl L. Gordon, and Erez Chimovits. The holders maintain registration rights for their remaining securities under a previously established Registration Rights Agreement.